PDF下载 ( 1564 KB)
Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma
-
摘要:
目的观察重组人血管内皮抑制素（恩度）联合肝动脉介入治疗对中晚期肝癌无疾病进展生存期的影响。方法选取2011年3月-2015年5月福建省肿瘤医院收治的86例中晚期肝癌患者,按照配对设计分为治疗组和对照组。治疗组（n=43）采用恩度联合肝动脉介入治疗;对照组（n=43）采用肝动脉介入治疗联合口服中药肝复乐。计数资料组间比较采用χ2检验,计量资料组间比较采用t检验。Kaplan-Meier法进行生存分析,单因素分析采用Log-rank法,多因素回归分析采用Cox比例风险模型。结果治疗组和对照组的中位无疾病进展生存期分别为154 d[95%可信区间（95%CI）:94214 d]、70 d（95%CI:39101 d）,两组比较差异具有统计学意义（χ2=10.741,P=0.001）。单因素分析显示,肝硬化严重程度、肿瘤个数、门静脉主干癌栓/下腔静脉癌栓是中晚期肝癌患者预后的影响因素（χ2值分别为8.182、9.150、6.565,P值分别为0.004、0.027、0.038）;多因素分析显示,肝硬化严重程度、门静脉主干癌栓/下腔静脉癌栓是恩度联合肝...
-
关键词:
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 化学疗法,肿瘤,局部灌注 /
- 血管抑制素类 /
- 治疗
Abstract:Objective To investigate the effect of recombinant human endostatin( Endostar) combined with hepatic artery interventional therapy on the progression- free survival( PFS) of patients with advanced hepatocellular carcinoma( HCC). Methods A total of 86 patients with advanced HCC who were admitted to Fujian Provincial Tumor Hospital from March 2011 to May 2015 were selected and divided into treatment group and control group according to a matched pair design. The treatment group( 43 patients) was given Endostar combined with hepatic artery interventional therapy,and the control group( 43 patients) was given hepatic artery interventional therapy combined with oral administration of Ganfule. The chi- square test was applied for comparison of categorical data between the two groups,and the t- test was applied for comparison of continuous data between the two groups. The Kaplan- Meier method was applied for survival analysis,the Log- rank test was applied for univariate analysis,and Cox proportional hazards model was applied for multivariate analysis. Results The median PFS in the treatment group and the control group was 154 d [95% confidence interval( CI) : 94- 214 d]and 70 d( 95% CI: 39- 101d),respectively,with a significant difference between the two groups( χ2= 10. 741,P = 0. 001). Univariate analysis showed that the severity of liver cirrhosis,number of tumors,and main portal vein tumor thrombus / inferior vena cava tumor thrombus were the prognostic factors for patients with advanced HCC( χ2= 8. 182,9. 150,and 6. 565,P = 0. 004,0. 027,and 0. 038); multivariate analysis showed that the severity of liver cirrhosis and main portal vein tumor thrombus / inferior vena cava tumor thrombus were the independent prognostic factors for PFS in patients with advanced HCC who were treated with Endostar combined with hepatic artery interventional therapy( P = 0. 028 and 0.013). Conclusion Endostar can effectively prolong the PFS of patients with advanced HCC after hepatic artery interventional therapy,but it does not have a clear advantage in patients with severe liver cirrhosis or main portal vein tumor thrombus / inferior vena cava tumor thrombus.
-
[1]YE SL,QIN SK,WU MC,et al.Consensus on standardized diagnosis and treatment of primary liver cancer[J].J Clin Hepatol,2009,25(2):83-92.(in Chinese)叶胜龙,秦叔逵,吴孟超,等.原发性肝癌规范化诊治的专家共识[J].临床肝胆病杂志,2009,25(2):83-92. [2]DIGTYAR AV,POZDNYAKOVA NV,FELDMAN NB,et al.Endostatin:current concepts about its biological role and mechanisms of action[J].Biochemistry(Mosc),2007,72(3):235-246. [3]HUANG X,WONG MK,ZHAO Q,et al.Soluble recombinant endostatin purified from Escherichia coli:antiangiogenic activity and antitumor effect[J].Cancer Res,2001,61(2):478-481. [4]LI B,WU XY,ZHOU H,et al.Acid-induced unfolding mechanism of recombinant human endostatin[J].Biochemistry,2004,43(9):2550-2557. [5]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159. [6] HAO MZ,LIN HL,CHEN QZ,et al.Efficacy of transcatheter arterial infusion alone or combined with transcatheter arterial chemoembolization on advanced hepatocellular carcinoma with portal vein tumor thrombus in the main trunk[J/OL].Contemp Interv Med,2015,1(3).http://www.intervmed.com/2015010316.html.(in Chinese)郝明志,林海澜,陈起忠,等.合并门脉主干癌栓的晚期肝癌肝动脉介入治疗的疗效观察[J/OL].当代介入医学,2015,1(3).http://www.intervmed.com/2015010316.html. [7]LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60. [8]WEI Y,TU R,CHEN ZM,et al.Hepatic functional reserve and prognosis after liver interventional therapy:evaluation by CT grading of liver cirrhosis[J].J Clin Radiol,2010,29(12):1671-1674.(in Chinese)韦勇,涂蓉,陈忠明,等.肝硬化CT分级评估肝癌介入治疗肝储备功能及预后研究[J].临床放射学杂志,2010,29(12):1671-1674. [9]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442. [10]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171. [11]MARUYAMA K,OCHIAI A,AKIMOTO S,et al.Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer[J].Oncology,2000,59(4):302-309. [12]ANDO E,TANAKA M,YAMASHITA F,et al.Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis:analysis of 48 cases[J].Cancer,2002,95(3):588-595. [13]KUDO M,MATSUI O,IZUMI N,et al.JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma:2014 update by the liver cancer study group of Japan[J].Liver Cancer,2014,3(3-4):458-468. [14]FOLKMAN J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607. [15]WANG JW,SUN Y,LIU YY,et al.Results of randomized,multicenter,double-blind phaseⅢtrial of rh-endostatin(YH-16)in treatment of advanced non-small cell lung cancer patients[J].Chin J Lung Cancer,2005,8(4):283-290.(in Chinese)王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. [16]LIU XF,QIN SK,WANG L,et al.Endostar combined with chemotherapy on the multiple kinds of advanced malignancies[J].Chin Clin Oncol,2007,12(4):241-245.(in Chinese)刘秀峰,秦叔逵,王琳,等.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察[J].临床肿瘤学杂志,2007,12(4):241-245. [17]REN TJ,SHAN FX,HOU JF,et al.Efficacy and safety of combined XELOX and Endostar therapy as first-line treatment for patients with advanced biliary tract carcinoma[J].Chin J Oncol Prev Treat,2015,7(1):41-44.(in Chinese)任铁军,单风晓,侯建峰,等.XELOX方案联合恩度一线治疗晚期胆系肿瘤的临床观察[J].中国癌症防治杂志,2015,7(1):41-44. [18]WANG YZ.Endostar infusion combined with interventional chemotherapy and embolization interventional therapy in treatment of advanced liver cancer[J].Modern Prevent Med,2011,38(2):399-341.(in Chinese)王永中.恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌的临床研究[J].现代预防医学,2011,38(2):399-341. [19]HAO MZ,CHEN WJ,LIN HL,et al.Efficacy of transcatheter arterial chemoembolization combined with Ganfule capsules on advanced hepatocellular carcinoma[J].Central South Pharm,2013,11(2):147-150.(in Chinese)郝明志,陈武进,林海澜,等.肝动脉栓塞化疗联合肝复乐胶囊治疗晚期肝癌临床疗效观察[J].中南药学,2013,11(2):147-150. [20]JEONG SW,JANG JY,SHIM KY,et al.Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis[J].Gut Liver,2013,7(6):696-703. [21]ZHANG Y,FAN W,WANG Y,et al.Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis:a retrospective analysis[J].Oncologist,2015,20(12):1417-1424. [22]MENG ZQ,LIU LM,MA X,et al.Prognosis risk factors and therapeutic effect analysis in primary hepatic carcinoma:394 cases report[J].China Oncol,2007,17(8):628-632.(in Chinese)孟志强,刘鲁明,马鑫,等.394例原发性肝癌的预后因素与疗效分析[J].中国癌症杂志,2007,17(8):628-632. [23]JIA QL,GAO WQ.Prognostic factors affecting TACE treatment in patients with primary hepatic carcinoma[J].J Henan Univ Sci Tech:Med Sci,2009,27(2):158-160.(in Chinese)贾群玲,高万勤.影响原发性肝癌病人TACE治疗的预后因素[J].河南科技大学学报:医学版,2009,27(2):158-160. 期刊类型引用(13)
1. 李书有. 中晚期肝癌的非手术综合治疗. 医学信息. 2022(09): 73-75+80 . 
百度学术2. 钟佑衡，吴斌，韩杲. 中医养阴清毒法结合肝动脉介入术治疗原发性肝癌的疗效观察. 现代诊断与治疗. 2021(06): 854-855 . 百度学术3. 祝晓蕾. 对肝动脉栓塞化疗后中晚期肝癌患者采取重组人血管内皮抑制素治疗的效果分析. 中国现代药物应用. 2021(16): 160-163 . 百度学术4. 平凡. 经导管动脉化疗栓塞术联合索拉非尼治疗中晚期肝细胞肝癌的效果及护理措施. 实用临床医药杂志. 2020(04): 122-124+128 . 百度学术5. 牛焕焕. 基于护理程序的整体护理干预在中晚期肝癌患者术后的应用. 黑龙江医药. 2020(02): 465-467 . 百度学术6. 周国永，陈秀梅，刘伟波，蒋本武，朱玉莉. 联用洛铂、表柔比星和丝裂霉素对原发性肝癌患者进行介入治疗的效果评价. 当代医药论丛. 2020(09): 36-38 . 百度学术7. 董燕. 重组人血管内皮抑制素持续静脉泵入联合吉西他滨联合顺铂方案化疗治疗晚期肺鳞癌患者的疗效评价. 中国药物与临床. 2020(13): 2219-2221 . 百度学术8. 程雄飞，俞远东，喻雄杰. ~(125)I粒子植入术联合吉西他滨TACE术治疗中晚期肝癌近期疗效及对肝功能、细胞免疫和预后的影响. 武汉大学学报(医学版). 2019(06): 912-916 . 百度学术9. 冷松. 洛铂联合表柔比星、丝裂霉素在肝癌介入治疗中的应用观察. 影像研究与医学应用. 2018(15): 198-199 . 百度学术10. 许军，施长杲，秦汉林，朱先海，谢韬，周磊，费一鹏，王伟昱. 益气养阴解毒方对晚期肝癌介入治疗减毒增效作用的临床研究. 安徽医药. 2017(03): 541-545 . 百度学术11. 方艳秋，米旭光，李首庆，魏海峰，许淑芬，谭岩. 重组鼠白细胞介素18在肝癌小鼠体内的抗肿瘤作用. 吉林大学学报(医学版). 2017(03): 550-554 . 百度学术12. 张世军，姜秋颖. 恩度联合化疗治疗消化系统晚期癌症的临床研究进展. 现代肿瘤医学. 2017(13): 2178-2182 . 百度学术13. 米旭光，刘磊，李首庆，魏海峰，许淑芬，谭岩，方艳秋. 应用rmIL-18诱导肿瘤特异性CTL治疗肝癌的实验研究. 中国免疫学杂志. 2017(04): 545-548 . 百度学术其他类型引用(2)
-
百度学术
下载:
